PL3908282T3 - Leczenie raka z mutacjami genetycznymi gnaq lub gna11 za pomocą inhibitorów kinazy białkowej c - Google Patents

Leczenie raka z mutacjami genetycznymi gnaq lub gna11 za pomocą inhibitorów kinazy białkowej c

Info

Publication number
PL3908282T3
PL3908282T3 PL20703606.2T PL20703606T PL3908282T3 PL 3908282 T3 PL3908282 T3 PL 3908282T3 PL 20703606 T PL20703606 T PL 20703606T PL 3908282 T3 PL3908282 T3 PL 3908282T3
Authority
PL
Poland
Prior art keywords
gna11
gnaq
inhibitors
cancer
treatment
Prior art date
Application number
PL20703606.2T
Other languages
English (en)
Inventor
John Knox
Mark Lackner
Zineb MOUNIR
Carol O'brien
Original Assignee
Ideaya Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ideaya Biosciences, Inc. filed Critical Ideaya Biosciences, Inc.
Publication of PL3908282T3 publication Critical patent/PL3908282T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL20703606.2T 2019-01-07 2020-01-07 Leczenie raka z mutacjami genetycznymi gnaq lub gna11 za pomocą inhibitorów kinazy białkowej c PL3908282T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962789177P 2019-01-07 2019-01-07
PCT/US2020/012542 WO2020146355A1 (en) 2019-01-07 2020-01-07 Treatment of cancer having gnaq or gna11 genetic mutations with protein kinase c inhibitors

Publications (1)

Publication Number Publication Date
PL3908282T3 true PL3908282T3 (pl) 2025-12-15

Family

ID=69467733

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20703606.2T PL3908282T3 (pl) 2019-01-07 2020-01-07 Leczenie raka z mutacjami genetycznymi gnaq lub gna11 za pomocą inhibitorów kinazy białkowej c

Country Status (10)

Country Link
US (1) US20220305008A1 (pl)
EP (2) EP3908282B1 (pl)
DK (1) DK3908282T3 (pl)
FI (1) FI3908282T3 (pl)
HR (1) HRP20251266T1 (pl)
LT (1) LT3908282T (pl)
PL (1) PL3908282T3 (pl)
PT (1) PT3908282T (pl)
RS (1) RS67265B1 (pl)
WO (1) WO2020146355A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250017921A1 (en) 2020-09-08 2025-01-16 Ideaya Biosciences Inc. Pharmaceutical combination and tumor treatment
WO2022221586A1 (en) * 2021-04-15 2022-10-20 Ideaya Biosciences, Inc. Combination therapy comprising a pkc inhibitor and a mek inhibitor
WO2024044774A2 (en) * 2022-08-26 2024-02-29 Ideaya Biosciences, Inc. Methods of treating uveal melanoma with a pkc inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013531469A (ja) * 2010-04-16 2013-08-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 黒色腫におけるgna11およびgnaqのエキソン4変異
JO3589B1 (ar) * 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها

Also Published As

Publication number Publication date
EP3908282B1 (en) 2025-07-02
HRP20251266T1 (hr) 2025-12-05
DK3908282T3 (da) 2025-10-06
LT3908282T (lt) 2025-10-27
PT3908282T (pt) 2025-10-15
RS67265B1 (sr) 2025-10-31
EP4653052A2 (en) 2025-11-26
EP3908282A1 (en) 2021-11-17
FI3908282T3 (fi) 2025-10-10
WO2020146355A1 (en) 2020-07-16
US20220305008A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
IL279587A (en) Protein tyrosine phosphatase inhibitors and methods of using them
IL286462A (en) Protein tyrosine phosphatase inhibitors
IL280099A (en) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
EP3980199A4 (en) Sanitization and cleaning system for objects
EP4079735A4 (en) Compound for inhibiting and inducing degradation of egfr kinase
EP3601285A4 (en) THERAPEUTIC AGENT FOR THE INHIBITION OF PHOSPHODIESTERASE AND ITS RELATED DISORDERS
SI3986897T1 (sl) Inhibitor EGFR za zdravljenje raka
PL3908282T3 (pl) Leczenie raka z mutacjami genetycznymi gnaq lub gna11 za pomocą inhibitorów kinazy białkowej c
EP3423451A4 (en) INHIBITORS OF WDR5 PROTEIN PROTEIN BINDING
MX2021015826A (es) Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
IL284434A (en) Fibroblast activation protein inhibitors
EP3983386A4 (en) ACSS2 INHIBITORS AND METHODS OF USE THEREOF
EP4041212C0 (en) MEK INHIBITORS FOR THE TREATMENT OF HANTAVIRUS INFECTIONS
EP3377630A4 (en) Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
EP3439656A4 (en) DOUBLE SMALL MOLECULE INHIBITORS OF TRPV4 AND TRPA1 FOR DISINFECTION AND ANESTHESIA
PL3976597T3 (pl) Inhibitory małocząsteczkowe kinazy indukującej nf-kb
EP3262041A4 (en) Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
CL2018001724A1 (es) Terapia combinada de inhibidores de proteinas extra-terminales y bromodominio
PT3915989T (pt) Inibidor de jak e método de preparação do mesmo
LT3532059T (lt) Bromodomeno ir papildomo galinio baltymo inhibitorių derinio terapija
EP3897622A4 (en) Arginase inhibitors and methods of use
EP3787629A4 (en) CYCLINE-DEPENDENT KINASE INHIBITORS
EP3768386A4 (en) GENE THERAPY FOR THE TREATMENT OF BONE DISORDERS
IL280343A (en) Treatment of mucopolysaccharidosis iva
EP4058015A4 (en) ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF